← Alle mensen

KC

Ke-Neng Chen

10 publicaties

PubMed → Google Scholar →

Publicaties op Oncologisch.com

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 september 2025
Totale overleving with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.
The New England journal of medicine · 21 augustus 2025
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 april 2025
Neoadjuvant plus adjuvant pembrolizumab versus neoadjuvante chemo-IO alleen bij NSCLC: KEYNOTE-671 OS update
Lancet (London, England) · 28 september 2024
Perioperatieve pembrolizumab bij vroeg NSCLC: KEYNOTE-671 fase III
The New England journal of medicine · 10 augustus 2023
Neoadjuvant nivolumab plus chemotherapie bij resectabel longcarcinoom: CheckMate 816 fase III
The New England journal of medicine · 26 mei 2022
Gefitinib versus vinorelbine-cisplatine als adjuvant bij EGFR-gemuteerd NSCLC: ADJUVANT/CTONG1104 OS
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 maart 2021
Erlotinib versus gemcitabine-cisplatine als neoadjuvant bij stadium IIIA-N2 EGFR-gemuteerd NSCLC: EMERGING
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 september 2019
Ruimtelijk-temporele falingspatronen van adjuvant gefitinib: ADJUVANT/CTONG1104 post-hoc
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2019-03
Gefitinib versus vinorelbine-cisplatine als adjuvant bij stadium II-IIIA EGFR-gemuteerd NSCLC: ADJUVANT/CTONG1104
The Lancet. Oncology · 2018-01